CIBC Bancorp USA Inc. Acquires Shares of 243,718 AbbVie Inc. $ABBV

CIBC Bancorp USA Inc. acquired a new stake in AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 243,718 shares of the company’s stock, valued at approximately $56,430,000.

A number of other hedge funds also recently modified their holdings of ABBV. Vanguard Group Inc. grew its stake in AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after acquiring an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new stake in AbbVie during the second quarter worth approximately $4,288,200,000. Legal & General Group Plc boosted its holdings in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after acquiring an additional 493,420 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ABBV shares. Piper Sandler increased their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Guggenheim reissued a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Trading Down 5.1%

Shares of ABBV stock opened at $208.47 on Thursday. The stock has a market cap of $368.62 billion, a P/E ratio of 88.34, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a 50 day simple moving average of $223.76 and a 200 day simple moving average of $224.84.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year collaboration with AbbVie to advance a next‑generation antibody discovery platform, providing upfront and milestone payments and potential pipeline upside. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: Legendary investor Ken Fisher has AbbVie among notable portfolio moves for 2026, signaling continued institutional interest that can support the stock over the medium term. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Positive Sentiment: Zacks highlights AbbVie as a strong value pick based on style scores and fundamentals, which may attract value-oriented buyers amid short‑term weakness. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: Technically, ABBV slipped below its 50‑day moving average, signaling short‑term weakness to traders but it remains above the 200‑day average, so the long‑term trend is intact. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
• Neutral Sentiment: Market commentary (MSN/Benzinga) notes the share move largely reflects competitor progress rather than new AbbVie-specific fundamentals—useful for context but not new company data. What’s Going On With AbbVie Stock Today?
• Neutral Sentiment: High‑level policy reporting shows TrumpRx price lists aren’t uniformly cheaper than the UK, a reminder of ongoing pricing and regulatory scrutiny in pharma but not an AbbVie‑specific action today. TrumpRx lists many medicines at prices higher than paid in UK
• Negative Sentiment: FDA approved J&J’s oral IL‑23 inhibitor (Icotyde), the first oral peptide that blocks IL‑23 and a direct competitive threat to Skyrizi/Tremfya; J&J expects this class could reach blockbuster sales, increasing pressure on AbbVie’s pricing and market share in psoriasis. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: several outlets report ABBV shares fell sharply today after the J&J approval, indicating investor concern about near‑term revenue impact for Skyrizi. AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment
• Negative Sentiment: Legal risk: a U.S. appeals court revived a whistleblower suit accusing big drugmakers of overcharging programs for low‑income patients, reviving potential litigation and settlement exposure for major pharma names. Big drugmakers must face US overcharge claims on medications for low-income patients

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.